照護端生物感測器市場 - 全球產業規模、佔有率、趨勢、機會和預測，按產品、平台、最終用戶區域和競爭細分，2019-2029 年

2023 年全球照護端生物感測器市場估值為 730.1 億美元，預計在預測期內將強勁成長，到 2029 年複合年成長率為 7.89%。快速成長和技術進步為標誌的更廣泛的醫療保健行業。照護端生物感測器是創新設備，旨在在患者所在地或附近提供即時診斷訊息，透過消除集中實驗室測試的需要來簡化醫療保健專業人員的決策。該市場涵蓋各種生物感測器技術，例如電化學、光學和壓電感測器，每種技術在靈敏度、特異性和便攜性方面都具有獨特的優勢。推動全球市場擴張的因素包括糖尿病、心血管疾病和傳染病等慢性病的盛行率不斷上升，需要及時、精確的診斷解決方案。此外，對個人化醫療的需求不斷成長以及家庭醫療保健解決方案的採用也推動了對床邊生物感測器的需求不斷成長。奈米技術、微流體和無線連接的進步也增強了這些設備的性能和可用性，進一步推動市場成長。

市場概況
預測期	2025-2029
2023 年市場規模	730.1億美元
2029 年市場規模	1154.1億美元
2024-2029 年複合年成長率	7.89%
成長最快的細分市場	血糖監測
最大的市場	北美洲

受惠於完善的醫療基礎設施、高額醫療支出和政府支持舉措，北美和歐洲引領全球市場。然而，由於醫療保健支出的增加、醫療保健基礎設施的改善以及對現場診斷優勢的認知不斷提高，預計亞太地區未來幾年將顯著成長。儘管成長前景廣闊，但該市場仍面臨監管障礙、報銷問題以及將生物感測器整合到現有醫療保健系統的複雜性等挑戰。儘管如此，產業參與者、研究機構和醫療保健提供者之間的合作，加上研發投資，預計將推動創新並克服這些挑戰。全球照護端生物感測器市場為致力於開發具有成本效益、方便用戶使用且可靠的生物感測器解決方案的公司提供了利潤豐厚的機會，這些解決方案可提高患者治療效果並改變全球醫療保健服務。

主要市場促進因素

慢性病盛行率上升

越來越重視早期疾病檢測

生物感測器技術的技術進步

主要市場挑戰

監管障礙

報銷問題

與現有醫療保健系統整合

主要市場趨勢

轉向個人化醫療

家庭醫療保健需求不斷成長

細分市場洞察

產品洞察

區域洞察

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：客戶之聲

第 5 章：全球照護端生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 依產品（血糖監測、HIV、C型肝炎、懷孕）
  • 按平台（微流體、試紙條、免疫測定）
  • 按最終使用者（醫院和診所、藥房、其他）
  • 按地區
  • 按公司分類 (2023)
• 市場地圖
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按地區

第 6 章：亞太地區即時生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 澳洲
  • 日本
  • 韓國

第 7 章：歐洲即時護理生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 西班牙
  • 義大利
  • 英國

第 8 章：北美照護端生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 9 章：南美洲照護端生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲照護端生物感測器市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按產品分類
  • 按平台
  • 按最終用戶
  • 按國家/地區
• MEA：國家分析
  • 南非
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 埃及

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布（如有）
• 併購（如有）

第 13 章：全球照護端生物感測器市場：SWOT 分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• Abbott Laboratories Inc.
• Koninklijke Philips NV
• GE HealthCare Technologies Inc
• Accubiotech Co, Ltd.
• ACON Laboratories, Inc
• Becton, Dickinson and Company
• Biolytical Laboratories Inc.
• Danaher Corporation (HemoCue)
• Siemens Healthineers AG
• Meridian Bioscience, Inc

第 16 章：策略建議

第17章調查會社について,免責事項

Global Point-of-care Biosensors Market was valued at USD 73.01 Billion in 2023 and is anticipated to project robust growth in the forecast period with a CAGR of 7.89% through 2029. The Global Point-of-care Biosensors Market is a dynamic segment within the broader healthcare industry, marked by rapid growth and technological advancements. Point-of-care biosensors are innovative devices designed to deliver real-time diagnostic information at or near the patient's location, streamlining decision-making for healthcare professionals by eliminating the need for centralized laboratory testing. This market encompasses various biosensor technologies, such as electrochemical, optical, and piezoelectric sensors, each offering distinct advantages in sensitivity, specificity, and portability. Driving the expansion of the global market are factors like the increasing prevalence of chronic diseases such as diabetes, cardiovascular diseases, and infectious diseases, which necessitate timely and precise diagnostic solutions. Furthermore, the rising demand for personalized medicine and the adoption of home-based healthcare solutions are contributing to the growing demand for point-of-care biosensors. Advancements in nanotechnology, microfluidics, and wireless connectivity are also enhancing the performance and usability of these devices, further propelling market growth.

Market Overview
Forecast Period	2025-2029
Market Size 2023	USD 73.01 Billion
Market Size 2029	USD 115.41 Billion
CAGR 2024-2029	7.89%
Fastest Growing Segment	Glucose Monitoring
Largest Market	North America

North America and Europe lead the global market, benefiting from well-established healthcare infrastructure, high healthcare expenditure, and supportive government initiatives. However, significant growth is anticipated in the Asia-Pacific region in the coming years due to rising healthcare expenditure, improving healthcare infrastructure, and increasing awareness about the advantages of point-of-care diagnostics. Despite promising growth prospects, the market faces challenges such as regulatory hurdles, reimbursement issues, and the complexity of integrating biosensors into existing healthcare systems. Nonetheless, collaborations between industry players, research institutions, and healthcare providers, coupled with investments in research and development, are expected to drive innovation and surmount these challenges. The Global Point-of-care Biosensors Market offers lucrative opportunities for companies aiming to develop cost-effective, user-friendly, and reliable biosensor solutions that enhance patient outcomes and transform healthcare delivery worldwide.

Key Market Drivers

Rising Prevalence of Chronic Diseases

The escalating incidence of chronic ailments is a key driver propelling the expansion of the Global Point-of-care Biosensors Market. Chronic conditions like diabetes, cardiovascular ailments, and infectious diseases are placing substantial strains on healthcare systems worldwide, fueling the demand for efficient diagnostic solutions. Point-of-care biosensors provide swift and user-friendly testing capabilities, facilitating early detection and treatment management of these enduring health issues.

Diabetes, notably, has attained epidemic proportions globally, with cases continuing to soar. Point-of-care biosensors play a pivotal role in diabetes management by furnishing patients with real-time insights into their blood glucose levels, enabling prompt adjustments to medication, diet, and lifestyle. These devices empower diabetes patients to closely monitor their condition, mitigating the risk of complications and enhancing overall quality of life. Cardiovascular diseases, encompassing heart disease and stroke, stand as leading causes of mortality worldwide. Point-of-care biosensors can identify biomarkers linked to cardiac events, such as troponin levels, facilitating swift diagnosis and intervention during emergencies. By furnishing immediate information at the point of care, these biosensors aid healthcare providers in delivering timely treatment, thereby improving patient outcomes and alleviating the burden on healthcare facilities.

Infectious diseases also significantly contribute to the growing demand for point-of-care biosensors. The ongoing COVID-19 pandemic has underscored the significance of rapid diagnostic testing in curbing the spread of infectious diseases. Point-of-care biosensors capable of detecting viral antigens or antibodies play a critical role in screening, diagnosis, and surveillance efforts, enabling early case identification and prompt implementation of public health measures. The aging population and evolving lifestyles are further driving the surge in chronic disease prevalence globally. As individuals live longer and encounter increased exposure to risk factors such as sedentary lifestyles, unhealthy diets, and environmental pollutants, the incidence of chronic conditions continues to escalate. Point-of-care biosensors offer a convenient and accessible solution for monitoring and managing these chronic diseases, empowering individuals to proactively address their health concerns.

Growing Emphasis on Early Disease Detection

The increasing focus on early disease detection drives the growth of the Global Point-of-care Biosensors Market. Early disease detection is crucial for enhancing patient outcomes, facilitating timely intervention and treatment, resulting in improved prognosis and reduced healthcare expenditures. Point-of-care biosensors play a vital role in early disease detection by offering rapid and precise diagnostic testing outside conventional laboratory environments.

A key advantage of point-of-care biosensors is their capability to deliver instant results at the point of care, enabling healthcare professionals to initiate treatment promptly. This is particularly critical for conditions where early intervention is paramount, such as cancer, infectious diseases, and cardiovascular diseases. Point-of-care biosensors can identify biomarkers associated with these diseases, enabling early diagnosis and facilitating timely referral to specialized care as necessary. Cancer, a leading cause of morbidity and mortality globally, necessitates early detection for enhancing survival rates. Point-of-care biosensors capable of detecting cancer biomarkers in blood, urine, or other bodily fluids offer a promising avenue for early cancer detection. These biosensors facilitate screening and diagnosis in primary care settings, enabling timely detection of tumors before they become symptomatic or progress to advanced stages.

Infectious diseases also benefit from early detection through point-of-care biosensors, particularly in outbreak situations or resource-limited settings. Rapid diagnostic tests for infectious diseases like malaria, HIV, and tuberculosis enable healthcare providers to promptly identify cases and implement appropriate treatment and control measures, mitigating transmission and preventing further disease spread. Point-of-care biosensors serve as valuable tools for early detection and management of chronic diseases like diabetes and cardiovascular diseases. By providing patients with real-time health status information, these devices empower individuals to monitor their condition closely and make informed decisions regarding treatment and lifestyle choices. Early detection of complications such as hyperglycemia or hypertension can help avert serious adverse events and enhance long-term health outcomes.

Technological Advancements in Biosensor Technologies

Technological advancements in biosensor technologies are driving growth in the Global Point-of-care Biosensors Market. These innovations are transforming diagnostics by enhancing the sensitivity, accuracy, user-friendliness, and cost-effectiveness of point-of-care biosensors.

Miniaturization stands out as a key advancement propelling point-of-care biosensors. Compact and portable, miniaturized biosensors require minimal sample volumes, making them ideal for testing in diverse healthcare settings, including clinics, hospitals, and remote areas. This downsizing owes to progress in microfabrication techniques and nanotechnology, enabling the creation of lightweight biosensor devices easily integrated into handheld or wearable platforms. Increased sensitivity is another vital advancement. Heightened sensitivity allows biosensors to detect analytes at very low concentrations, enhancing their accuracy in diagnosing diseases and identifying early-stage biomarkers. Innovations in sensor design, surface chemistry, and signal amplification techniques contribute to significant sensitivity improvements, boosting point-of-care biosensor performance across various applications.

Enhanced connectivity capabilities also contribute to market growth. Modern biosensors feature wireless communication technologies like Bluetooth and Wi-Fi, facilitating seamless data transfer to smartphones, tablets, or cloud-based platforms. This connectivity enables remote patient data monitoring, real-time sharing of test results with healthcare providers, and integration with electronic health records, improving point-of-care diagnostics efficiency and accessibility. Advancements in biosensor technologies have led to multiplexed and multiparametric biosensors capable of simultaneously detecting multiple analytes in a single sample. These biosensors offer benefits such as reduced sample volume requirements, faster testing times, and cost savings. Such capabilities are particularly valuable in applications like infectious disease diagnostics, where simultaneous detection of multiple pathogens or biomarkers is crucial for accurate diagnosis and treatment.

Key Market Challenges

Regulatory Hurdles

One of the primary challenges facing the Global Point-of-care Biosensors Market is navigating complex regulatory landscapes. Obtaining regulatory approvals for new biosensor devices can be a lengthy and expensive process, involving rigorous testing and documentation requirements. Differences in regulatory requirements across regions further complicate matters, requiring manufacturers to navigate multiple regulatory frameworks. Delays in obtaining regulatory approvals can hinder market entry and slow down innovation, stifling growth in the point-of-care biosensors market.

Reimbursement Issues

Another significant challenge for the Global Point-of-care Biosensors Market is the lack of adequate reimbursement policies for point-of-care diagnostic tests. Reimbursement policies vary widely between countries and regions, and many healthcare systems do not provide adequate reimbursement for point-of-care testing. This lack of reimbursement poses a financial barrier for patients and healthcare providers, limiting the adoption of point-of-care biosensors. Without proper reimbursement mechanisms in place, the market viability of these devices may be compromised, hindering their widespread adoption and utilization in clinical practice.

Integration with Existing Healthcare Systems

Integrating point-of-care biosensors into existing healthcare systems presents a significant challenge for manufacturers and healthcare providers alike. Compatibility issues with electronic health record systems, data management protocols, and interoperability standards can impede seamless integration of biosensor data into clinical workflows. Moreover, healthcare professionals may require additional training to use point-of-care biosensors effectively, further complicating integration efforts. Addressing these integration challenges is essential to maximize the utility and impact of point-of-care biosensors in healthcare delivery.

Key Market Trends

Shift towards Personalized Medicine

The shift towards personalized medicine is significantly boosting the Global Point-of-care Biosensors Market, reshaping how healthcare is delivered and diagnostic solutions are utilized. Personalized medicine, also known as precision medicine, involves tailoring medical treatment to individual patient characteristics, such as genetic makeup, lifestyle factors, and disease biomarkers. Point-of-care biosensors are playing a crucial role in facilitating personalized medicine by providing real-time diagnostic information at the patient's location, enabling healthcare providers to make informed treatment decisions based on personalized patient data.

One of the key advantages of point-of-care biosensors in personalized medicine is their ability to deliver rapid and accurate diagnostic results outside traditional laboratory settings. These devices empower healthcare professionals to obtain timely information about a patient's health status, enabling them to customize treatment plans based on individual patient needs. For example, in oncology, point-of-care biosensors can detect cancer biomarkers in blood or tissue samples, allowing for early detection of tumors and targeted therapy selection based on the tumor's molecular profile.

Additionally, point-of-care biosensors enable patients to actively participate in their healthcare decisions by providing them with access to real-time diagnostic data. Patients can monitor their health conditions conveniently and proactively, leading to better self-management of chronic diseases and improved treatment adherence. This level of patient engagement and empowerment is essential for achieving optimal treatment outcomes in personalized medicine.

Furthermore, the adoption of point-of-care biosensors supports the broader goals of personalized medicine by facilitating the implementation of precision diagnostics and targeted therapies. These devices enable healthcare providers to identify specific disease biomarkers and molecular targets, allowing for the development of tailored treatment strategies that maximize therapeutic efficacy and minimize adverse effects. By delivering precise and actionable diagnostic information, point-of-care biosensors contribute to the optimization of patient care in personalized medicine.

Rising Demand for Home-based Healthcare

The rising demand for home-based healthcare is significantly boosting the Global Point-of-care Biosensors Market, transforming the way healthcare is delivered and diagnostic solutions are utilized. Home-based healthcare refers to the provision of medical services and monitoring of health conditions in patients' homes, rather than in traditional clinical settings. Point-of-care biosensors play a pivotal role in enabling home-based healthcare by providing rapid and convenient diagnostic testing capabilities that empower patients to monitor their health conditions conveniently and proactively.

One of the key advantages of point-of-care biosensors in home-based healthcare is their ability to deliver immediate results at the point of care. These devices enable patients to perform diagnostic tests in the comfort of their homes, eliminating the need for frequent visits to healthcare facilities. Patients can monitor their health conditions regularly, track changes in their biomarkers, and take proactive measures to manage chronic diseases effectively. This level of self-management empowers patients to take control of their health and improve their overall well-being.

Point-of-care biosensors enable remote monitoring of patients' health conditions by healthcare providers, allowing for timely intervention and personalized care. Healthcare professionals can remotely access patients' diagnostic data in real-time, enabling them to identify potential health issues early and adjust treatment plans accordingly. This proactive approach to healthcare management can lead to better outcomes, reduced hospitalizations, and improved patient satisfaction.

Furthermore, the adoption of point-of-care biosensors supports the broader goals of home-based healthcare by enhancing accessibility to medical services and reducing healthcare costs. These devices enable patients to perform diagnostic tests at home without the need for specialized equipment or trained personnel, saving time and resources associated with traditional laboratory testing. By decentralizing diagnostic testing and shifting care delivery to patients' homes, point-of-care biosensors contribute to the optimization of healthcare resources and the improvement of healthcare efficiency. The rising demand for home-based healthcare is driven by various factors, including an aging population, increasing prevalence of chronic diseases, and advancements in telemedicine technologies. As healthcare systems worldwide face challenges such as limited healthcare infrastructure and rising healthcare costs, there is a growing emphasis on shifting healthcare delivery from traditional clinical settings to patients' homes. Point-of-care biosensors play a critical role in enabling this transition by providing rapid, convenient, and cost-effective diagnostic testing solutions that support home-based healthcare delivery.

Segmental Insights

Product Insights

Based on the product, the glucose monitoring segment emerged as the dominant segment in the global point-of-care biosensors market in 2023. The increasing prevalence of diabetes globally has propelled the demand for glucose monitoring devices. With diabetes becoming a major public health concern, there is a growing need for convenient and accurate methods of monitoring blood glucose levels to manage the condition effectively. Point-of-care glucose biosensors offer a rapid and convenient way to measure blood glucose levels, empowering individuals with diabetes to monitor their condition closely and make informed decisions about their treatment and lifestyle.

Regional Insights

North America emerged as the dominant player in the global point-of-care biosensors market in 2023, holding the largest market share. North America boasts a robust healthcare infrastructure and a highly developed healthcare ecosystem, which fosters innovation and adoption of advanced medical technologies. The region is home to numerous leading healthcare institutions, research organizations, and medical device companies that drive advancements in point-of-care biosensors. Additionally, strong government support for healthcare innovation, coupled with favorable regulatory policies, accelerates the commercialization and adoption of point-of-care biosensors in North America.

Key Market Players

Abbott Laboratories Inc.

Koninklijke Philips N.V.

Accubiotech Co, Ltd.

ACON Laboratories, Inc

Becton, Dickinson and Company

Biolytical Laboratories Inc.

Danaher Corporation (HemoCue)

Siemens Healthineers AG

Meridian Bioscience, Inc

GE HealthCare Technologies Inc.

Report Scope:

In this report, the Global Point-of-care Biosensors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Point-of-care Biosensors Market, By Product:

Glucose Monitoring HIV Hepatitis C Pregnancy

Point-of-care Biosensors Market, By Platforms:

Microfluidics Dipsticks Immunoassays

Point-of-care Biosensors Market, By End-User:

Hospitals & Clinics Pharmacy Others

Point-of-care Biosensors Market, By Region:

North America

United States

Canada

Mexico

Europe

France

United Kingdom

Italy

Germany

Spain

Asia-Pacific

China

India

Japan

Australia

South Korea

South America

Brazil

Argentina

Colombia

Middle East & Africa

South Africa

Saudi Arabia

UAE

Egypt

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Point-of-care Biosensors Market.

Available Customizations:

Global Point-of-care Biosensors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of customer

5. Global Point-of-care Biosensors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Glucose Monitoring, HIV, Hepatitis C, Pregnancy)
  • 5.2.2. By Platforms (Microfluidics, Dipsticks, Immunoassays)
  • 5.2.3. By End User (Hospitals & Clinics, Pharmacy, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2023)
• 5.3. Market Map
  • 5.3.1. By Product
  • 5.3.2. By Platforms
  • 5.3.3. By End User
  • 5.3.4. By Region

6. Asia Pacific Point-of-care Biosensors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Platforms
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Point-of-care Biosensors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Platforms
      • 6.3.1.2.3. By End User
  • 6.3.2. India Point-of-care Biosensors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Platforms
      • 6.3.2.2.3. By End User
  • 6.3.3. Australia Point-of-care Biosensors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Platforms
      • 6.3.3.2.3. By End User
  • 6.3.4. Japan Point-of-care Biosensors Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product
      • 6.3.4.2.2. By Platforms
      • 6.3.4.2.3. By End User
  • 6.3.5. South Korea Point-of-care Biosensors Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product
      • 6.3.5.2.2. By Platforms
      • 6.3.5.2.3. By End User

7. Europe Point-of-care Biosensors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Platforms
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Point-of-care Biosensors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Platforms
      • 7.3.1.2.3. By End User
  • 7.3.2. Germany Point-of-care Biosensors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Platforms
      • 7.3.2.2.3. By End User
  • 7.3.3. Spain Point-of-care Biosensors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Platforms
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Point-of-care Biosensors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Platforms
      • 7.3.4.2.3. By End User
  • 7.3.5. United Kingdom Point-of-care Biosensors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Platforms
      • 7.3.5.2.3. By End User

8. North America Point-of-care Biosensors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Platforms
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Point-of-care Biosensors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Platforms
      • 8.3.1.2.3. By End User
  • 8.3.2. Mexico Point-of-care Biosensors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Platforms
      • 8.3.2.2.3. By End User
  • 8.3.3. Canada Point-of-care Biosensors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Platforms
      • 8.3.3.2.3. By End User

9. South America Point-of-care Biosensors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Platforms
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Point-of-care Biosensors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Platforms
      • 9.3.1.2.3. By End User
  • 9.3.2. Argentina Point-of-care Biosensors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Platforms
      • 9.3.2.2.3. By End User
  • 9.3.3. Colombia Point-of-care Biosensors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Platforms
      • 9.3.3.2.3. By End User

10. Middle East and Africa Point-of-care Biosensors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Platforms
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Point-of-care Biosensors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Platforms
      • 10.3.1.2.3. By End User
  • 10.3.2. Saudi Arabia Point-of-care Biosensors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Platforms
      • 10.3.2.2.3. By End User
  • 10.3.3. UAE Point-of-care Biosensors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Platforms
      • 10.3.3.2.3. By End User
  • 10.3.4. Egypt Point-of-care Biosensors Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Product
      • 10.3.4.2.2. By Platforms
      • 10.3.4.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches (If Any)
• 12.3. Mergers & Acquisitions (If Any)

13. Global Point-of-care Biosensors Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Abbott Laboratories Inc.
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Koninklijke Philips N.V.
• 15.3. GE HealthCare Technologies Inc
• 15.4. Accubiotech Co, Ltd.
• 15.5. ACON Laboratories, Inc
• 15.6. Becton, Dickinson and Company
• 15.7. Biolytical Laboratories Inc.
• 15.8. Danaher Corporation (HemoCue)
• 15.9. Siemens Healthineers AG
• 15.10. Meridian Bioscience, Inc

16. Strategic Recommendations

17. About Us & Disclaimer